Invetx, Inc., a pioneer in protein-based therapeutics for animal health, has announced that it has agreed to be acquired by Dechra Pharmaceuticals Limited (Dechra), an international veterinary pharmaceuticals business, for up to US$520 million in total consideration on a cash-free and debt-free basis. The acquisition remains subject to antitrust approval and other customary closing conditions.

Latham & Watkins LLP represents Invetx in the transaction with a corporate deal team led by Boston/New York partner Kristen Grannis, Boston partner Spencer Ricks, and Boston counsel Gloria Ring, with associates Andrew Rondeau and Christine Kalpin. Advice was also provided on benefits and compensation matters by Boston partner Josh Friedman, with associate Tessa Young; on tax matters by Bay Area partner Grace Lee, with associate Dennis Poehland; on antitrust matters by Bay Area partner Josh Holian and Washington, D.C. partners Ian Conner and Patrick English, with associate Ehson Kashfipour; on intellectual property matters by Boston partner Sarah Gagan and New York counsel Eliot Choy, with associate Arun Mohan; on data privacy matters by Bay Area partner Heather Deixler, with associate Mitch Bennett; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with associate Meryl Bartlett; and on EU regulatory matters by Brussels/Paris partner Eveline Van Keymeulen, with associate Jeanne Fabre.